Not exact matches
A study by investigators at Brigham and Women's Hospital (BWH) published this week in PLOS ONE
identifies four factors that may account for sex differences in statin
therapy among patients with coronary artery disease (CAD),
pointing to interventions and additional research that will be needed to help overcome this sex disparity and reduce cardiovascular risk for women.
Nevertheless, trying to develop new
therapies based on what treatments will look like in the coming decade is a nearly impossible task,
points out Michael Stratton, joint head of the Cancer Genome Project and professor of cancer genetics at the University of London's Institute of Cancer Research, who has been working on developing finely targeted cancer treatments since
identifying the BRAF oncogene in 2002.
«If one could
identify the mechanism, it might
point us in the direction of new, better
therapies.»
While the researchers can not yet
point to a potential therapeutic application of their findings,
identifying genetic changes that underlie MND is the first step in finding ways to manipulate these changes using gene
therapy.
The central
points of immunology are
identifying and distinguishing the many different immune cells that are essential for diagnosis and
therapy.
In the area of personalized medicine, it is highly pertinent to not only predict the drug response at early time
points during the
therapy, but also to be able to
identify the optimal drug combination for an individual patient.
Then, we could try to
identify the mechanisms that regulate that set
point, showing us the kind of
therapy that's likely to be effective.